In a 2024 cryo-EM structure paper published in Cell Discovery, researchers resolved retatrutide bound to each of the three receptors and showed the same peptide adopting a continuous alpha-helical conformation across all three, with receptor-specific contacts in the extracellular loops that tune potency at each target
arthralgia incidence in trials is generally similar to placebo Rapid weight loss from GLP-1 treatment may alter biomechanical loading on joints, causing temporary adjustment-related discomfort Patients prescribed GLP-1 medications often have type 2 diabetes or obesity, conditions independently associated with increased osteoarthritis rates Seek medical advice for severe, worsening, or persistent joint pain, or if accompanied by swelling, redness, warmth, or systemic symptoms Report suspected medication side effects through the MHRA Yellow Card scheme to support ongoing safety monitoring Table of Contents Understanding GLP-1 Medications and Their Common Side Effects GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), most commonly cause gastrointestinal side effects such as nausea, vomiting, and diarrhoea
Consistent with these effects, the GLP-1 activity of MEDI4166 in the ex-vivo cAMP accumulation assay was maintained out to 21 days in contrast to Ab#2.1_EX4 which approached baseline levels on day 7 (Supplementary Fig
Navigating the complexities of GLP-1 therapy can often be daunting
